Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study

BACKGROUND/AIMS: Efficacy and safety data of alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), is not yet well established in the Korean population. We assessed them in ODYSSEY-KT through the pre-specified Korean subanalysis. METHODS: In the ODYS...

Descripción completa

Detalles Bibliográficos
Autores principales: Nam, Chang-Wook, Kim, Dong-Soo, Li, Jianyong, Baccara-Dinet, Marie T., Li, Ivy, Kim, Ji-Hyun, Kim, Chong-Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Internal Medicine 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6823573/
https://www.ncbi.nlm.nih.gov/pubmed/30257549
http://dx.doi.org/10.3904/kjim.2018.133

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6823573/
https://www.ncbi.nlm.nih.gov/pubmed/30257549
http://dx.doi.org/10.3904/kjim.2018.133

Ejemplares similares